secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001558370-23-002694
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure reports FY2022 net loss of $74.7M; cash $159.9M, runway into mid-2025
------------------------------------------------------------------------------

- Net loss of $74.7M for FY2022 vs $69.4M in FY2021, driven by higher R&D expenses.
- Cash, equivalents, and marketable securities $159.9M at Dec 31, 2022, down from $219.6M.
- R&D expenses $54.2M (FY2022) vs $50.2M (FY2021); G&A $21.7M vs $20.6M.
- NC410 Phase 1b/2 combo with pembrolizumab update expected mid-2023; NC762 update Q4 2023.
- NC525 dosed first patient in Phase 1 AML trial Feb 2023; initial data expected Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000155837023002694/0001558370-23-002694-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000155837023002694/nxtc-20230302x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-002694

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer